Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prestige Consumer Healthcare (PBH) Cost of Revenue: 2009-2025

Historic Cost of Revenue for Prestige Consumer Healthcare (PBH) over the last 16 years, with Sep 2025 value amounting to $122.5 million.

  • Prestige Consumer Healthcare's Cost of Revenue fell 3.06% to $122.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $487.5 million, marking a year-over-year decrease of 2.01%. This contributed to the annual value of $503.3 million for FY2025, which is 0.48% up from last year.
  • According to the latest figures from Q3 2025, Prestige Consumer Healthcare's Cost of Revenue is $122.5 million, which was up 12.21% from $109.2 million recorded in Q2 2025.
  • In the past 5 years, Prestige Consumer Healthcare's Cost of Revenue ranged from a high of $132.1 million in Q1 2023 and a low of $100.7 million during Q1 2021.
  • In the last 3 years, Prestige Consumer Healthcare's Cost of Revenue had a median value of $125.2 million in 2024 and averaged $124.4 million.
  • As far as peak fluctuations go, Prestige Consumer Healthcare's Cost of Revenue grew by 19.53% in 2021, and later declined by 9.84% in 2025.
  • Prestige Consumer Healthcare's Cost of Revenue (Quarterly) stood at $119.4 million in 2021, then climbed by 4.78% to $125.1 million in 2022, then decreased by 0.25% to $124.8 million in 2023, then grew by 3.58% to $129.3 million in 2024, then fell by 3.06% to $122.5 million in 2025.
  • Its Cost of Revenue was $122.5 million in Q3 2025, compared to $109.2 million in Q2 2025 and $126.5 million in Q1 2025.